Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer

Abstract

The aim of this study was, (1) to characterize the serum protein binding of lerisetron, a new 5-hydroxytryptamine (5-HT3) receptor antagonist under investigation as an antiemetic agent, and (2) to measure the percentage of unbound lerisetron in cancer patients. The binding parameters were determined in human serum albumin (HSA), α1-acid glycoprotein (AAG… (More)
DOI: 10.1007/s002800050839

Topics

3 Figures and Tables

Cite this paper

@article{Calvo1998SerumPB, title={Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer}, author={Rosario Calvo and Rosa M. Jim{\'e}nez and Ignacio F. Troc{\'o}niz and Elena Su{\'a}rez and Ana Gonzalo and Ma Luisa Lucero and Ewa Raczka and Aurelio Orjales}, journal={Cancer Chemotherapy and Pharmacology}, year={1998}, volume={42}, pages={418-422} }